Increased Fall Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer.
To examine the relationship between the use of androgen deprivation therapy (ADT) and the subsequent risk of falls in men with prostate cancer (PC) by employing a population-based dataset. We retrieved the study sample from the Taiwan Longitudinal Health Insurance Database 2005. We included 886 patients with PC who had received ADT as the study group, whereas 862 patients with PC who had not received ADT served as the comparison group. We then individually tracked each study patient for a 3-year period to identify those who subsequently received a diagnosis of a fall. We performed Cox proportional hazard regressions to calculate the hazard ratio (HR) and its corresponding 95% confidence interval (CI) for a fall during the 3-year follow-up period between these 2 groups. The incidence rates of falls per 1000 person-years were 13.37 (95% CI: 9.15~18.88) and 6.44 (95% CI: 3.61~10.63), respectively, for patients with PC who received ADT and those who did not receive ADT. Furthermore, the hazard ratio for a fall during the 3-year follow-up period for patients with PC who had received ADT was 1.95 (95% CI: 1.04~3.66, P = .037) compared to those who had not received ADT after censoring sampled patients who died during the 3-year follow-up period and adjusting for age, geographical location, monthly income, urbanization level, hypertension, diabetes, hyperlipidemia, coronary heart disease, Parkinson's disease, epilepsy, stroke, and mental illness. The present findings suggest that patients with PC who had received ADT had an increased risk of falls.